Lansoprazole (Synonyms: AG-1749)

Name: Lansoprazole
Brand: MedChemExpress
SKU: HY-13662
Rating: 5.0 (2 reviews)

Cat. No.: HY-13662 Purity: 99.83%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).

For research use only. We do not sell to patients.

Lansoprazole Chemical Structure

CAS No. : 103577-45-3

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 61	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 61	In-stock	Estimated Time of Arrival: December 31
Solid
500 mg	USD 55	In-stock	Estimated Time of Arrival: December 31
1 g	USD 79	In-stock	Estimated Time of Arrival: December 31
5 g	USD 343	In-stock	Estimated Time of Arrival: December 31
10 g		Get quote
50 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Other Forms of Lansoprazole:

2 Publications Citing Use of MCE Lansoprazole

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Phospholipase Isoform Specific Products:

View All Isoforms

Phospholipase A PLD Phospholipase C

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
AGS	IC₅₀	149 μM Compound: Lansoprazole	Cytotoxic activity against human AGS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxic activity against human AGS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 26009162]
AGS	IC₅₀	162 μM Compound: Lansoprazole	Cytotoxicity against human AGS cells after 24 hrs by neutral red uptake assay Cytotoxicity against human AGS cells after 24 hrs by neutral red uptake assay	[PMID: 20359186]
BXPC-3	IC₅₀	124 μM Compound: lansoprazole	Inhibition of FASN in human BxPC3 cells assessed as inhibition of [14C]acetate incorporation preincubated for 4 hrs before [14C]acetate addition measured after 2 hrs by scintillation counting Inhibition of FASN in human BxPC3 cells assessed as inhibition of [14C]acetate incorporation preincubated for 4 hrs before [14C]acetate addition measured after 2 hrs by scintillation counting	[PMID: 25513712]
BXPC-3	IC₅₀	6.71 μM Compound: lansoprazole	Inhibition of survival of human BxPC3 cells after 10 to 14 days by crystal violet staining-based colony formation assay Inhibition of survival of human BxPC3 cells after 10 to 14 days by crystal violet staining-based colony formation assay	[PMID: 25513712]
Fibroblast	IC₅₀	291 μM Compound: Lansoprazole	Cytotoxic activity against human fibroblasts assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxic activity against human fibroblasts assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 26009162]
HEK-293T	IC₅₀	24.38 μM Compound: Lansoprazole	Inhibition of recombinant human C-MYC/DDK-tagged ENGase expressed in HEK293T cells using heat inactivated bovine ribonuclease B as substrate pretreated for 15 mins followed by substrate addition after 90 mins by SDS-PAGE analysis Inhibition of recombinant human C-MYC/DDK-tagged ENGase expressed in HEK293T cells using heat inactivated bovine ribonuclease B as substrate pretreated for 15 mins followed by substrate addition after 90 mins by SDS-PAGE analysis	[PMID: 28512024]
HEK-293T	IC₅₀	8.2 μM Compound: Lansoprazole	Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis	[PMID: 23122865]
HEK-293T	IC₅₀	94 μM Compound: Lansoprazole	Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis	[PMID: 23122865]
HepG2	IC₅₀	221 μM Compound: Lansoprazole	Cytotoxicity against human HepG2 cells after 24 hrs by neutral red uptake assay Cytotoxicity against human HepG2 cells after 24 hrs by neutral red uptake assay	[PMID: 20359186]
MRC5	IC₅₀	306 μM Compound: Lansoprazole	Cytotoxicity against human MRC5 cells after 24 hrs by neutral red uptake assay Cytotoxicity against human MRC5 cells after 24 hrs by neutral red uptake assay	[PMID: 20359186]
PANC-1	IC₅₀	93 μM Compound: lansoprazole	Inhibition of FASN in human PANC1 cells assessed as inhibition of [14C]acetate incorporation preincubated for 4 hrs before [14C]acetate addition measured after 2 hrs by scintillation counting Inhibition of FASN in human PANC1 cells assessed as inhibition of [14C]acetate incorporation preincubated for 4 hrs before [14C]acetate addition measured after 2 hrs by scintillation counting	[PMID: 25513712]

In Vitro

Lansoprazole from 0.3 to 3 μM inhibits gastric acid formation in a concentration-dependent manner (IC₅₀ of 0.76 μM)^[4].
? Lansoprazole (30-300 μM) both induced concentration-dependent, reversible and reproducible relaxations of arteries^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Lansoprazole (20-40 mg/kg) treatment significantly attenuated STZ and HFD -induced memory deficits, biochemical and histopathological alterations^[3].
? Lansoprazole (20 mg/kg and 40 mg/kg, p.o.) significantly reduces the STZ and HFD- induced increase in AChE activity^[3].
? Lansoprazole (20 mg/kg and 40 mg/kg, p.o.) significantly reduces the STZ and HFD- induced rise in brain MPO level^[3].
? Further HFD mice treated with lansoprazole (20 mg/kg and 40 mg/kg, p.o.) shows a marked decrease in the body weight in comparison to the control animals^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Swiss albino mice (20–25 g) of either sex^[3].
Dosage:	20 mg/kg, 40 mg/kg.
Administration:	PO, started after second dose of STZ and then subjected to MWM test. Continued (30 min before) during the acquisition trial conducted from day 1 to day 4.
Result:	Significantly attenuated the day 4 rise in ELT and decreased in day 5 TSTQ in the STZ as well as HFD treated mice in a dose dependent manner.

Clinical Trial

Molecular Weight

369.36

Formula

C₁₆H₁₄F₃N₃O₂S

CAS No.

103577-45-3

Appearance

Solid

Color

White to off-white

SMILES

O=S(C1=NC2=CC=CC=C2N1)CC3=NC=CC(OCC(F)(F)F)=C3C

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (270.74 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 10 mg/mL (27.07 mM; Need ultrasonic)

H₂O : < 0.1 mg/mL (insoluble)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.7074 mL	13.5369 mL	27.0739 mL
5 mM	0.5415 mL	2.7074 mL	5.4148 mL
10 mM	0.2707 mL	1.3537 mL	2.7074 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.83%

Select Batch:

Data Sheet (275 KB) SDS (393 KB)

COA (247 KB) HNMR (274 KB) LCMS (93 KB)

Handling Instructions (2659 KB)

References

[1]. Kokufu, T., et al., Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol, 1995. 48(5): p. 391-5. [Content Brief]

[2]. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330. [Content Brief]

[3]. Rupinder K Sodhi, et al. Defensive effect of lansoprazole in dementia of AD type in mice exposed to streptozotocin and cholesterol enriched diet. PLoS One. 2013 Jul 31;8(7):e70487. [Content Brief]

[4]. Jun Matsukawa, et al. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011 May 1;81(9):1145-51. [Content Brief]

[5]. Erdinc Naseri, et al. Proton pump inhibitors omeprazole and lansoprazole induce relaxation of isolated human arteries. Eur J Pharmacol. 2006 Feb 15;531(1-3):226-31. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

Ethanol / DMSO	1 mM	2.7074 mL	13.5369 mL	27.0739 mL	67.6846 mL
	5 mM	0.5415 mL	2.7074 mL	5.4148 mL	13.5369 mL
	10 mM	0.2707 mL	1.3537 mL	2.7074 mL	6.7685 mL
	15 mM	0.1805 mL	0.9025 mL	1.8049 mL	4.5123 mL
	20 mM	0.1354 mL	0.6768 mL	1.3537 mL	3.3842 mL
	25 mM	0.1083 mL	0.5415 mL	1.0830 mL	2.7074 mL
DMSO	30 mM	0.0902 mL	0.4512 mL	0.9025 mL	2.2562 mL
	40 mM	0.0677 mL	0.3384 mL	0.6768 mL	1.6921 mL
	50 mM	0.0541 mL	0.2707 mL	0.5415 mL	1.3537 mL
	60 mM	0.0451 mL	0.2256 mL	0.4512 mL	1.1281 mL
	80 mM	0.0338 mL	0.1692 mL	0.3384 mL	0.8461 mL
	100 mM	0.0271 mL	0.1354 mL	0.2707 mL	0.6768 mL

Lansoprazole Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Lansoprazole103577-45-3AG-1749AG1749AG 1749Proton PumpBacterialPhospholipaseSTZHFDgastricacidexosomeN-SMaseELTTSTQInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Lansoprazole (Synonyms: AG-1749)

Customer Review

Other Forms of Lansoprazole:

Lansoprazole Related Antibodies

2 Publications Citing Use of MCE Lansoprazole

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Phospholipase Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Lansoprazole Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Lansoprazole Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report